NGL Fine-ChemNSE:NGLFINE -0.55%82 PS Ratio is 3.94 as of Jul. 13, 2026, which is 45% above its 10-year median of 2.71. GuruFocus rates NSE:NGLFINE with a GF Score™ of 82/100 and a GF Value™ of ₹2,828.92 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, NGL Fine-Chem ranks worse than 67.43% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NGL Fine-Chem's share price is ₹3193.60.
NGL Fine-Chem's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹811.31. Hence, NGL Fine-Chem's PS Ratio for today is 3.94.
Warning Sign:
NGL Fine-Chem Ltd stock PS Ratio (=3.93) is close to 1-year high of 3.93.
The historical rank and industry rank for NGL Fine-Chem's PS Ratio or its related term are showing as below:
NSE:NGLFINE'
s PS Ratio Range Over the Past 10 Years
Min: 1 Med: 2.71 Max: 7.47
Current: 3.93
During the past 13 years, NGL Fine-Chem's highest PS Ratio was 7.47. The lowest was 1.00. And the median was 2.71.
NSE:NGLFINE's PS Ratio is ranked worse than 67.43% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs NSE:NGLFINE: 3.93
During the past 12 months, the average Revenue per Share Growth Rate of NGL Fine-Chem was 36.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 22.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.70% per year.
During the past 13 years, NGL Fine-Chem's highest 3-Year average Revenue per Share Growth Rate was 40.00% per year. The lowest was 5.60% per year. And the median was 21.20% per year.
Back to Basics: PS Ratio
NGL Fine-Chem (NSE:NGLFINE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NGL Fine-Chem PS Ratio Related Terms
NGL Fine-Chem PS Ratio Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: PS Ratio Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's PS Ratio distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NGL Fine-Chem's Share Price of today is ₹3193.60. NGL Fine-Chem's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹811.31.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
NGL Fine-Chem (NSE:NGLFINE) has a PS Ratio of 3.94 as of Jul. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NGL Fine-Chem and its competitors. This is 45% above median its historical median of 2.71. Over the past decade, NGL Fine-Chem's PS Ratio has ranged from 1.00 to 7.47. According to the industry distribution chart, NGL Fine-Chem ranks #644 out of 955 companies in the Drug Manufacturers industry, placing it in the top 67.4%.
Is NGL Fine-Chem's PS Ratio too high?
NGL Fine-Chem's current PS Ratio of 3.94 is 45% above median its 10-year median of 2.71. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.47. The Drug Manufacturers industry median PS Ratio is 2.30. NGL Fine-Chem's value of 3.94 is 71.3% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #644 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #644 out of 955 companies for PS Ratio. This places NGL Fine-Chem in the lower half of its industry. The industry median PS Ratio is 2.30. NGL Fine-Chem's value of 3.94 is 71.3% above this benchmark. Historically, NGL Fine-Chem's own PS Ratio has ranged from 1.00 to 7.47 over the past decade. While the company's 10-year median is 2.71 vs. the industry median of 2.30, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current PS Ratio of 3.94 is 71.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current PS Ratio is 3.94, which is 45% above median its own 10-year median of 2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,828.92, compared to a current price of ₹3,193.60 — trading 12.9% above its estimated fair value. The current PS Ratio is 3.94, which is 45% above median its 10-year median of 2.71 and 71.3% above the Drug Manufacturers industry median of 2.30. NGL Fine-Chem's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current PS Ratio is 3.94 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,193.60 is trading 12.9% above its estimated GF Value™ of ₹2,828.92.
GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.
Key valuation signals for NSE:NGLFINE:
PS Ratio: 3.94 (45% above median its 10-year median of 2.71)
GF Value™: ₹2,828.92 vs. price of ₹3,193.60 (12.9% above fair value)
Industry Position: 71.3% above the Drug Manufacturers median (#644 of 955)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
82GF Score
Get the complete analysis for NSE:NGLFINE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
